JPS63150209A - Skin cosmetic - Google Patents
Skin cosmeticInfo
- Publication number
- JPS63150209A JPS63150209A JP29816086A JP29816086A JPS63150209A JP S63150209 A JPS63150209 A JP S63150209A JP 29816086 A JP29816086 A JP 29816086A JP 29816086 A JP29816086 A JP 29816086A JP S63150209 A JPS63150209 A JP S63150209A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- molecular weight
- aminobutyric acid
- effect
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 23
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000002378 acidificating effect Effects 0.000 claims abstract description 12
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 11
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 10
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 8
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920000045 Dermatan sulfate Polymers 0.000 claims abstract description 5
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 5
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims abstract description 5
- 229940051593 dermatan sulfate Drugs 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 abstract description 30
- 230000007306 turnover Effects 0.000 abstract description 10
- 239000006210 lotion Substances 0.000 abstract description 9
- 230000032683 aging Effects 0.000 abstract description 8
- 239000002884 skin cream Substances 0.000 abstract description 6
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 76
- 238000012360 testing method Methods 0.000 description 21
- 210000004927 skin cell Anatomy 0.000 description 16
- 239000000126 substance Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229940124277 aminobutyric acid Drugs 0.000 description 8
- 210000000434 stratum corneum Anatomy 0.000 description 8
- 230000003712 anti-aging effect Effects 0.000 description 7
- -1 hyaluronic acid thorium salt Chemical class 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- AOKCDAVWJLOAHG-UHFFFAOYSA-N 4-(methylamino)butyric acid Chemical compound C[NH2+]CCCC([O-])=O AOKCDAVWJLOAHG-UHFFFAOYSA-N 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- NPSJHQMIVNJLNN-UHFFFAOYSA-N 2-ethylhexyl 4-nitrobenzoate Chemical compound CCCCC(CC)COC(=O)C1=CC=C([N+]([O-])=O)C=C1 NPSJHQMIVNJLNN-UHFFFAOYSA-N 0.000 description 2
- 239000004808 2-ethylhexylester Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000000736 corneocyte Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000036620 skin dryness Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- TUAXNBXNWXXFJC-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;sulfuric acid Chemical compound OS(O)(=O)=O.OC(=O)[C@@H](N)CCCNC(N)=N TUAXNBXNWXXFJC-WCCKRBBISA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 108700016947 Bos taurus structural-GP Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 150000008535 L-arginines Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
少なくとも一種と、Ｔ−アミノ酪酸及びその誘導体より
選ばれた少なくとも一種とを配合してなる皮膚老化防止
効果（荒肌改善効果、角質改善効果、角質層のターンオ
ーバーを速くする効果、美肌効果等）に優れた皮膚化粧
料に関する。DETAILED DESCRIPTION OF THE INVENTION A skin anti-aging effect (improving effect on rough skin, improving effect on dead skin cells, suppressing turnover of stratum corneum) obtained by blending at least one type with at least one type selected from T-aminobutyric acid and its derivatives. The present invention relates to skin cosmetics with excellent skin care effects, skin beautification effects, etc.
（従来技術）
老化皮膚とは、乾燥して滑らかさのない荒れた肌で、角
質細胞の剥離現象が認められ、結合組織はコラーゲン／
エラスチン比が高く、しわが多い。また、老化皮膚は細
胞代謝の低下により角質層のターンオーバーが遅く、従
って皮膚に老化防止効果が付与発現するとターンオーバ
ーが速くなると言われ、種々の皮膚細胞賦活成分や血行
促進成分を配合した皮膚化粧料が提案されている。(Prior art) Aging skin is dry, rough skin that lacks smoothness, exhibits exfoliation of corneocytes, and connective tissue that is composed of collagen/
High elastin ratio and many wrinkles. In addition, in aging skin, the turnover of the stratum corneum is slow due to a decline in cell metabolism. Therefore, it is said that the turnover becomes faster when anti-aging effects are applied to the skin. Cosmetics have been proposed.
しかし、従来より提案された皮膚化粧料のいずれもが、
例えば、しっとりした肌にする、滑らかな肌にする等の
皮膚表面の改善に資することはできても、積極的に老化
皮膚防止効果を期待する程に優れた皮膚化粧料を得るこ
とは困難であった。However, all of the skin cosmetics that have been proposed so far,
For example, although it may be possible to improve the skin surface by making the skin moist and smooth, it is difficult to obtain skin cosmetics that are so good that they can be expected to actively prevent aging skin. there were.
皮膚老化防止効果を期待するためには、皮膚細胞賦活作
用又は血行促進作用を有する成分を皮膚化粧料に配合す
ることが、適当なる技術的条件であっても、それだけの
技術的要素のみで、期待する程度の老化防止効果が発現
するものではない。In order to expect an anti-aging effect on the skin, even if it is an appropriate technical condition to incorporate ingredients that have skin cell activating effects or blood circulation promoting effects into skin cosmetics, it is not necessary to use only those technical factors. It does not exhibit the expected anti-aging effect.
即ち、皮膚細胞は、真皮層に存在する皮膚毛細血管より
滲出する皮膚細胞賦活成分や皮膚細胞の栄養素を取り込
んで、正常な細胞代謝を営んでいる。That is, skin cells take in skin cell activating components and skin cell nutrients exuded from skin capillaries present in the dermal layer, and carry out normal cell metabolism.
しかし、真皮にあっては、その構成成分、特に構造性糖
蛋白とともに、線維性蛋白の間隙を埋めている酸性ムコ
多糖類、例えば、ヒアルロン酸、デルマタン硫酸、コン
ドロイチン硫酸、ヘパラン硫酸等の成分から構成される
真皮の基質成分、或いは表皮にあっては、基底細胞、有
線細胞、顆粒細胞そして角質細胞の間隙を埋めているリ
ンパ液や脂質類及び酸性ムコ多糖類等から構成されてい
る開光物質層を皮膚細胞賦活成分等が泳動し、真皮では
線維芽細胞等、表皮では基底細胞や有線細胞等に到達し
、該成分がそれぞれの細胞内に円滑に取り込まれて初め
て、期待せる老化防止効果が発現するのである。However, in the dermis, its constituent components, especially structural glycoproteins, as well as acidic mucopolysaccharides that fill the gaps between fibrous proteins, such as hyaluronic acid, dermatan sulfate, chondroitin sulfate, heparan sulfate, etc. The matrix component of the dermis, or in the epidermis, the light-enhancing substance layer, which is composed of lymph fluid, lipids, acidic mucopolysaccharides, etc. that fills the spaces between basal cells, wire cells, granule cells, and corneocytes. The skin cell activation ingredients migrate and reach fibroblasts in the dermis, basal cells and wired cells in the epidermis, and only when these ingredients are smoothly incorporated into each cell can the expected anti-aging effect occur. It is expressed.
然るに、老化皮膚は、表皮細胞層が非薄化していると共
に、表皮細胞層中の基質及び開光物質を構成する成分で
あるリンパ液や酸性ムコ多Ｉ！頚等の成分の存在量が減
少し、そのため末梢血管から滲出してくる皮膚細胞賦活
成分や皮膚細胞の栄養素は基質成分層や開光物質層を充
分泳動し得す、細胞の該成分の取り込みが充分行われず
、従って老化防止効果が期待する程度に発現しない。However, in aging skin, the epidermal cell layer is not thinned, and at the same time, lymph fluid and acid mucopolymerase, which are components of the matrix and light-dispersing substances in the epidermal cell layer, are not thinned. The amount of components present in the neck and other areas decreases, and as a result, skin cell activating components and skin cell nutrients exuded from peripheral blood vessels can sufficiently migrate through the matrix component layer and light-enhancing substance layer, and the uptake of these components by cells is reduced. It is not carried out sufficiently and therefore the anti-aging effect is not expressed to the expected extent.
かかる皮膚毛細血管と皮膚細胞との間に介在する基質成
分や開光物質の構成を正常化して、皮膚細胞賦活成分や
皮膚細胞の栄養素等が皮膚細胞に円滑に取り込まれるよ
うな成分を配合してなる皮膚化粧料の提案は未だ皆無で
ある。It normalizes the composition of matrix components and light-enhancing substances that are present between the skin capillaries and skin cells, and contains ingredients that allow skin cell activation components and skin cell nutrients to be smoothly taken into the skin cells. There are still no proposals for skin cosmetics.
（発明の開示）
そこで、本発明者は、叙上の考え方に基づき、基質成分
及び開光物質の正常化に資する酸性ムコ多Ｉ！ｉ類につ
いて、鋭意研究を重ねた結果、通常化粧料に配合される
酸性ムコ多糖類及びそれらの塩は、平均分子量が敵方か
ら数１００万という高分子であって、それらのものは殆
ど経皮吸収されずびその塩の少なくとも一種と、γ−ア
ミノ酪酸及びその誘導体の少なくとも一種とを併用配合
してなる皮膚化粧料は、本発明が目的とする皮膚細胞を
賦活し、老化皮膚のターンオーバーを速め、荒肌改善効
果、角質改善効果に著効を呈すると共に皮膚に湿潤性（
しっとり怒）、柔軟性（滑らか感）、弾力性（張り）及
び艶を付与し得る美肌効果をも発現することを確認して
本発明を完成するに至った。(Disclosure of the Invention) Therefore, based on the above-mentioned idea, the present inventor has developed an acidic mucopolymer I which contributes to the normalization of substrate components and light-opening substances! As a result of intensive research regarding Group I, we found that acidic mucopolysaccharides and their salts, which are usually blended into cosmetics, are polymers with an average molecular weight of several million molecules, and most of them are A skin cosmetic product containing at least one salt of γ-aminobutyric acid and at least one of its derivatives, which is absorbed through the skin, activates skin cells and improves the turnover of aging skin, which is the objective of the present invention. It has a remarkable effect on improving rough skin and keratin, and has moisturizing properties (
The present invention was completed after confirming that it also has beautifying effects that can impart moist skin, softness (smooth feel), elasticity (tightness), and luster.
（発明の目的）
即ち、本発明の目的は、荒肌改善効果、角質改善効果、
角質層のターンオーバーを速くする効果、美肌効果等の
皮膚老化防止効果に優れた皮膚化粧料を提供することに
ある。(Objective of the invention) That is, the object of the present invention is to improve rough skin, to improve keratin,
The purpose of the present invention is to provide a skin cosmetic that has excellent skin aging prevention effects such as the effect of accelerating the turnover of the stratum corneum and the effect of beautifying the skin.
少なくとも一種と、γ−ア、ミノ酪酸及びその誘導体よ
り選ばれた少なくとも一種とを配合したことを特徴とし
た皮膚化粧料である。This skin cosmetic is characterized by containing at least one type of the present invention and at least one selected from γ-a, minobutyric acid, and derivatives thereof.
（構成の具体的な説明）
本発明に用いる酸性ムコ多ｔｌｉ類、即ちヒアル口ン酸
、デルマタン硫酸、コンドロイチン硫酸、ヘパラン硫酸
等は公知の物質であって、軟骨、関節、眼球、皮膚その
他の結合組織に基質成分となって、蛋白質と結合して動
物体内に広く分布してい平均分子量１００万の市販され
ているヒアルロン酸ナトリウム５ｇを、０．０２Ｎの塩
酸水溶液に分散溶解し、ｐＨ＝２〜３に調製して充分に
撹拌しつつ温浴中で６５°Ｃに加温した。この加温処理
の時間を各々１０分から１２０分に変えることにより、
平均分子量が１万〜１０万のヒアルロン酸を得ることが
できる。(Specific explanation of the composition) The acidic mucotriates used in the present invention, ie, hyalutonic acid, dermatan sulfate, chondroitin sulfate, heparan sulfate, etc., are known substances, and are used in cartilage, joints, eyes, skin, etc. 5 g of commercially available sodium hyaluronate with an average molecular weight of 1 million, which forms a matrix component in connective tissue and is widely distributed in animal bodies by binding to proteins, was dispersed and dissolved in a 0.02N hydrochloric acid aqueous solution, and the pH was 2. 3 and heated to 65°C in a hot bath while stirring thoroughly. By changing the time of this heating treatment from 10 minutes to 120 minutes,
Hyaluronic acid having an average molecular weight of 10,000 to 100,000 can be obtained.
次いて、Ｎ−苛性ソーダで中和した後、該溶液を室温ま
で冷却し、エタノール３倍容を加えて得られる沈澱物を
遠心分離する。沈澱物をエタノールで洗浄した後、乾か
して低分子ヒアルロン酸塩の粉末を得た。また、この低
分子ヒアルロン酸すトリウム塩を酸で処理して、遊離の
ヒアルロン酸とし、次にこれを他の塩基性物質で処理し
て、例えば、カリウム塩、トリエタノールアミノ塩、Ｌ
平均分子量４万の市販されているコンドロイチン硫酸ナ
トリウム５ｇを、５０ｍ１の水に溶かし、アンバーライ
トＩＲ−１２０（Ｈ型）のレジンカラムに通して得られ
る流出液を充分に撹拌しつつ、温浴中で７５°Ｃに加温
した。この加温処理の時間を各々１０分から１２０分に
変えることにより、平均分子量２５００〜２６０００の
コンドロイチン硫酸を得ることができる。次いて、Ｎ−
苛性ソーダで中和する。該溶液を室温まで冷却後、エタ
ノール３倍容を加えて得られる沈澱物を遠心分離し、エ
タノールで洗滌した後、乾燥してコンドロイチン硫酸ナ
トリウム塩の粉末を得た。更に、コンドロイチン硫酸ナ
トリウムを酸で処理して遊離のコンドロイチン硫酸とし
２、次にこれを他の塩基性物質で処理して、例えば、カ
リウム塩、トリエタノールアミン塩、Ｌ−アルギニン塩
等のについても、上記コンドロイチン硫酸の例と同様の
処理により、遊離状或いはその塩類として調製した。After neutralizing with N-caustic soda, the solution is cooled to room temperature, 3 volumes of ethanol are added, and the resulting precipitate is centrifuged. The precipitate was washed with ethanol and dried to obtain a powder of low molecular weight hyaluronate. In addition, this low-molecular hyaluronic acid thorium salt is treated with an acid to obtain free hyaluronic acid, which is then treated with other basic substances, such as potassium salt, triethanolamino salt, L
5 g of commercially available sodium chondroitin sulfate with an average molecular weight of 40,000 was dissolved in 50 ml of water, and the resulting effluent was passed through a resin column of Amberlite IR-120 (H type) in a warm bath with sufficient stirring. Warmed to 75°C. By changing the time of each heating treatment from 10 minutes to 120 minutes, chondroitin sulfate having an average molecular weight of 2,500 to 26,000 can be obtained. Then, N-
Neutralize with caustic soda. After cooling the solution to room temperature, 3 times the volume of ethanol was added, and the resulting precipitate was centrifuged, washed with ethanol, and dried to obtain chondroitin sulfate sodium salt powder. Furthermore, sodium chondroitin sulfate is treated with acid to form free chondroitin sulfate2, which is then treated with other basic substances to obtain, for example, potassium salt, triethanolamine salt, L-arginine salt, etc. , was prepared as a free form or its salts by the same treatment as in the example of chondroitin sulfate.
尚、各処理時間により得られた酸性ムコ多Ｉｉ類の平均
分子量の測定方法は、ソモギーーネルソン（Ｓｏｍｏｇ
ｙｉ−Ｎｅｌｓｏｎ）法を用いた。In addition, the method for measuring the average molecular weight of acidic mucopolymer group II obtained for each treatment time is based on Somogyi-Nelson (Somogyi-Nelson).
yi-Nelson) method was used.
更に、本発明が目的としている荒肌改善効果、美肌効果
等の皮膚老化予防効果をより一層発揮させるため、併用
する血行促進剤についてスクリーニングしたところ、Ｔ
−アミノ酪酸及びその誘導体が最も本発明の目的として
期待せる効果を示した。Furthermore, in order to further exert the skin aging prevention effects such as improving rough skin and beautifying the skin, which are the objectives of the present invention, we screened blood circulation promoters to be used in combination, and found that T.
-Aminobutyric acid and its derivatives showed the most expected effects for the purpose of the present invention.
本発明に用いるＴ−アミノ酪酸は公知の物質であって、
植物界に広く遊離の形で存在し、動物では脳内に多く、
脳の代謝に重要な役割を果たし、脳血管障害の後遺症の
改善、筋萎縮症の改善に用いられている。また、該物質
の皮膚に対する作用としては皮膚末梢血管拡張作用によ
り皮膚作用を九進し、皮膚の疲労やたるみを治癒せしめ
、老化やしわを防止する作用があると言われている。T-aminobutyric acid used in the present invention is a known substance,
It exists widely in the plant kingdom in free form, and in animals it is abundant in the brain.
It plays an important role in brain metabolism and is used to improve the aftereffects of cerebrovascular disorders and muscular atrophy. In addition, the substance is said to have an effect on the skin by enhancing skin effects by dilating peripheral skin blood vessels, curing skin fatigue and sagging, and preventing aging and wrinkles.
また、γ−アミノ酪酸の誘導体として、Ｎ−メチル−γ
−アミノ酪酸又はＮ−ジメチル＝Ｔ−アミノ酪酸及びそ
れらのメチルエステル、エチルエステル、プロピルエス
テル、ブチルエステル等、またＮ−ジメチル−Ｔ−アミ
ノ酪酸の２−エチルヘキシルエステル、オクチルエステ
ル、オレイルエステル、ラウリルエステル、ヘキサデシ
ルエステル、ステアリルエステル等が知られているが、
これらＴ−アミノ酪酸及びその誘導体のいづれもが本発
明の皮膚化粧料に適用することができる。In addition, as a derivative of γ-aminobutyric acid, N-methyl-γ
-Aminobutyric acid or N-dimethyl=T-aminobutyric acid and their methyl esters, ethyl esters, propyl esters, butyl esters, etc., and 2-ethylhexyl ester, octyl ester, oleyl ester, lauryl ester of N-dimethyl-T-aminobutyric acid Esters, hexadecyl esters, stearyl esters, etc. are known, but
Any of these T-aminobutyric acids and their derivatives can be applied to the skin cosmetics of the present invention.
本発明者は、皮膚化粧料中に配合せる上記構成コ多ＩＩ
類及びその塩、（２）γ−アミノ醋酸及びその誘導体の
それぞれの配合量の比率（重量比）（１） ＝（２）
＝１ ：０．０１〜１：１である場合が好ましく、本発
明の目的とする優れた効果が認められた。The present inventor has proposed that the above-mentioned constituent components II to be incorporated into skin cosmetics.
and its salts, (2) γ-aminoacetic acid and its derivatives (weight ratio) (1) = (2)
=1:0.01 to 1:1 is preferable, and the excellent effects aimed at by the present invention were observed.
即ち、この（２）の血行促進剤が真皮に存在する皮膚末
梢毛細血管の血行を促進し、血液中に含まれている皮膚
細胞賦活成分や皮膚の栄養素の組織内滲出を活発にし、
更に、（１）が表皮細胞中に存在する基質成分の構成比
を改善することにより、皮膚細胞の皮膚細胞賦活成分等
の取り込みを円滑に行わしめ、皮膚の新陳代謝を促進し
、また（１）の優れた抱水能力が皮膚に適度の水分の付
与と保留に貢献し、しっとりとして滑らか、そしてはり
のある美肌効果を発現するという効能を発揮し得の塩と
Ｔ−アミノ酪酸及びその誘導体の配合割合は、総量を基
準として、（１）は０．０５〜２．０ｗｔ％、（２）は
０．０１〜２．０ｗｔ％あればよ、く、各々の配合量の
下限未満では、本発明の目的とする効果に充分ではなく
、一方、上限を越えても、その増加に見合った効果の向
上は望めないものである。That is, the blood circulation promoter (2) promotes blood circulation in the peripheral skin capillaries present in the dermis, activates the exudation of skin cell activating components and skin nutrients contained in the blood into the tissues,
Furthermore, (1) improves the composition ratio of matrix components present in epidermal cells, thereby facilitating the uptake of skin cell activation components, etc. into skin cells, promoting skin metabolism, and (1) The excellent water-holding ability of T-aminobutyric acid and its derivatives contributes to the provision and retention of an appropriate amount of moisture to the skin, making the skin moist, smooth, and firm. The blending ratio should be 0.05 to 2.0 wt% for (1) and 0.01 to 2.0 wt% for (2), based on the total amount. This is not sufficient to achieve the desired effect of the invention, and on the other hand, even if the upper limit is exceeded, no improvement in effect commensurate with the increase can be expected.
本発明の皮膚化粧料は、スキンクリーム、スキンローシ
ョン、スキンミルク、スキンパック、皮膚美容液等に適
用される。The skin cosmetics of the present invention are applicable to skin creams, skin lotions, skin milks, skin packs, skin serums, and the like.
尚、本発明の皮膚化粧料には上記構成成分の他に、色素
、香料、防腐剤、界面活性剤、顔料、抗酸化剤等を本発
明の目的を達成する範囲で適宜配合することができる。In addition to the above-mentioned components, the skin cosmetic of the present invention may contain pigments, fragrances, preservatives, surfactants, pigments, antioxidants, etc. as appropriate within the scope of achieving the purpose of the present invention. .
（実施例）
以下、実施例及び比較例に基づき本発明の詳細な説明す
る。(Examples) Hereinafter, the present invention will be described in detail based on Examples and Comparative Examples.
尚、荒肌改善効果試験、角質改善効果試験、角質層のタ
ーンオーバー測定試験、官能テスト（美肌効果試験）は
下記の通りである。The rough skin improvement effect test, the stratum corneum improvement effect test, the stratum corneum turnover measurement test, and the sensory test (skin beautification effect test) are as follows.
（１）荒肌改善効果試験
下脚に荒れ肌を有する中高年被験者２０名を対象として
４週間連続塗布効果を調べた。被験者の左側下脚試験部
位に１日１回約１ｇの試料を塗布し、試験開始前及び終
了後の皮膚の状態を下記の判定基準により判定した。右
側下脚は試料を塗布せず対照とした。(1) Effect test on improving rough skin The effect of continuous application for 4 weeks was investigated on 20 middle-aged and elderly subjects who had rough skin on their lower legs. Approximately 1 g of the sample was applied to the test site of the left lower leg of the subject once a day, and the condition of the skin before and after the test was judged according to the following criteria. No sample was applied to the right lower leg, which served as a control.
皮膚乾燥度の判定基準
−：正常
± ：軽微乾燥、落屑なし
＋ ：乾燥、落屑軽度
十＋：乾燥、落屑中等度
十＋十：乾燥、落屑顕著
試験前後の試験部位と対照部位の判定結果を比較し、皮
膚乾燥度が２段階以上改善された場合（例えば、＋→−
２＋＋→±）を有効、１段階改善された場合をやや有効
、変化がなかった場合を無効とした。試験結果は有効、
やや有効となった被験者の人数で示した。Judgment criteria for skin dryness -: Normal±: Slight dryness, no scaling If the skin dryness has improved by two or more levels (e.g. +→-
2++→±) was considered valid, one level improvement was considered somewhat effective, and no change was considered invalid. Test results are valid,
It is shown by the number of subjects who were somewhat effective.
（２）角質改善（角質細胞の抗剥離性増大）効果試験
前述の荒肌改善効果試験開始前及び終了後の被験者皮膚
にスコッチテープにチバンメンディングテープ）を接着
し、これを剥離した時テープに付着した角質細胞の状態
を走査型電子顕微鏡によって詳細に調べ、下記の基準に
よって皮膚角質細胞抗剥離性を解析し、角質改善効果を
求めた。(2) Effect test on improving keratin (increasing anti-exfoliation properties of keratinocytes) Scotch tape (Tiban mending tape) was adhered to the subject's skin before and after the above-mentioned rough skin improvement effect test, and when the tape was peeled off. The condition of the keratinocytes attached to the skin was examined in detail using a scanning electron microscope, and the skin keratinocyte anti-exfoliation property was analyzed according to the following criteria to determine the keratin improving effect.
角質改善効果（角質細胞抗剥離性増大）の判定基準
評価点１ニスケールを認めず
２：小スケール点在
３：小〜中スケール顕著
４：大スケール顕著
評価は４週間連続塗布後の試験部位の評価点と 一対照
部位のそれとの差が２点以上の場合を有効、１点の場合
をやや有効、０点の場合を無効とした。判定結果は有効
、やや有効となった被験者の人数で示した。Judgment criteria for keratin improving effect (increased anti-desquamation property of keratinocytes) Evaluation points: 1 No scale observed 2: Small scale scattered 3: Small to medium scale noticeable 4: Large scale noticeable The test was considered valid if the difference between the evaluation score and that of a control site was 2 or more points, slightly valid if it was 1 point, and invalid if it was 0 points. The judgment results are expressed as the number of subjects who found the test to be effective or somewhat effective.
（３）角質層のターンオーバー測定試験蛍光色素のダン
ジルクロライドを白色ワセリン中に５ｇ重量％配谷した
軟膏を作り、被験者２０名の前腕部の皮膚に２４時間閉
塞貼付し、角質層にダンジルクロライドを浸透結合させ
る。その後同じ部位に１日２回（朝・夕）試験試料を塗
布し、毎日ダンジルクロライドの蛍光を調べ、その蛍光
が消滅するまでの日数を皮膚角質層のターンオーバーと
した。(3) Test for measuring the turnover of the stratum corneum An ointment containing 5 g of the fluorescent dye danzyl chloride in white petrolatum was prepared and applied to the skin of the forearms of 20 subjects for 24 hours, and the ointment was applied to the skin of the forearms of 20 subjects. Osmotic bonding of diluchloride. Thereafter, the test sample was applied to the same area twice a day (morning and evening), and the fluorescence of danzyl chloride was checked every day, and the number of days until the fluorescence disappeared was defined as the turnover of the stratum corneum of the skin.
判定結果は被験者の日数の平均値で示した。尚、通常の
皮膚角質層のターンオーバーは１４〜１６日であるが、
老化した皮膚においては１８日前後にのびる。それに対
して老化防止効果が現れると１２日前後にまで短縮され
る。The judgment results were shown as the average value of the number of days of the subjects. Note that the normal turnover of the stratum corneum of the skin is 14 to 16 days,
In aging skin, it lasts for about 18 days. On the other hand, if the anti-aging effect appears, the time will be shortened to around 12 days.
（４）官能テスト（美肌効果試験）
荒れ肌、小皺、乾燥肌等を訴える女子被験者（３５〜５
５才）２０人に試料を１日２回（朝・夕）連続３ケ月後
の効果を評価した。試験結果は、皮膚の湿潤性、平滑性
、弾力性の各項目に対して、皮膚に潤いが生じた、皮膚
が滑らかになった、皮膚に張りが生じたと回答した人数
で示した。(4) Sensory test (skin beautification effect test) Female subjects (35-5
The effects were evaluated after 3 consecutive months of administering the sample to 20 children (5 years old) twice a day (morning and evening). The test results were shown by the number of people who answered that their skin was moisturized, smoothed, or taut for each item of skin wettability, smoothness, and elasticity.
比較例１〜Ｉ４、実施例１〜１０
〔二層型スキンローション〕
下記の組成の如く二層型スキンローション基剤にヒアル
ロン酸（以下、ＨＡと略記する）、ヒアルロン酸ナトリ
ウム（以下同様に、ＨＡ−Ｎａ）、コンドロイチン硫酸
（ＣｈＳ）、ヘパラン硫酸（Ｈｐｓ）、コンドロイチン
硫酸カリウム（Ｃｈｓ−Ｋ）、コンドロイチン硫酸トリ
エタノールミン（Ｃｈ ５−ＴＥＡ） 、デルマタン硫
酸（Ｄｓ）、テルマタン硫酸Ｌ−アルギニン（Ｄ ｓ
−Ａ）並びにγ−アミノ酪酸（ＧＡＢＡ） 、Ｎ−メチ
ル−γ−アミノ酪酸（Ｍ−ＧＡＢＡ） 、Ｎ−メチル−
ｒ−アミノ酪酸エチルエステル（Ｍ−ＧＡＢＡ−Ｅ）、
Ｎ−ジメチル−Ｔ−アミノ酪酸（ＤＭ−ＧＡＢＡ） 、
Ｎ−ジメチル−γ−アミノ酪酸ステアリルエステル（Ｄ
Ｍ−ＧＡＢＡ−３）等を第１表に記載の通りに配合して
、各々のスキンローシ（１）組成
（２）調製法
（Ｂ）成分の内、Ｔ−アミノ酪酸、Ｎ−メチル−Ｔ〜ル
アミノ酸及びそれらのメチルエステル、エチルエステル
、プロピルエステル、ブチルエステル等は水やアルコー
ルに易溶のため、（Ｃ）成分に（Ｄ）成分を混合溶解し
た溶液に、更に（Ｂ）成分を均一に混合溶解し、この溶
液に（＾）成分を撹拌しつつ均一に混合分散し、次いて
容器に充填する。Comparative Examples 1 to I4, Examples 1 to 10 [Two-layered skin lotion] Hyaluronic acid (hereinafter abbreviated as HA), sodium hyaluronate (hereinafter similarly, HA-Na), chondroitin sulfate (ChS), heparan sulfate (Hps), potassium chondroitin sulfate (Chs-K), chondroitin sulfate triethanolamine (Ch 5-TEA), dermatan sulfate (Ds), termatan sulfate L-arginine ( Ds
-A) and γ-aminobutyric acid (GABA), N-methyl-γ-aminobutyric acid (M-GABA), N-methyl-
r-aminobutyric acid ethyl ester (M-GABA-E),
N-dimethyl-T-aminobutyric acid (DM-GABA),
N-dimethyl-γ-aminobutyric acid stearyl ester (D
M-GABA-3) etc. are blended as shown in Table 1 to prepare each skin lotion (1) Composition (2) Preparation method (B) Among the ingredients, T-aminobutyric acid, N-methyl-T~ Since amino acids and their methyl esters, ethyl esters, propyl esters, butyl esters, etc. are easily soluble in water and alcohol, component (B) is added uniformly to a solution of component (D) mixed and dissolved in component (C). The (^) component is mixed and dispersed uniformly in this solution while stirring, and then filled into a container.
また、（Ｂ）成分の内、Ｎ−メチル−γ−アミノ酪酸ま
たはＮ−ジメチル−Ｔ−アミノ酪酸の２−エチルヘキシ
ルエステル、オクチルエステル、ステアリルエステル等
の油溶性物質については、予め（Ａ）成分中に混合溶解
せしめ、上記の方法と同様にして、二層型スキンローシ
ョンを調製する。In addition, among component (B), oil-soluble substances such as 2-ethylhexyl ester, octyl ester, and stearyl ester of N-methyl-γ-aminobutyric acid or N-dimethyl-T-aminobutyric acid should be prepared in advance as component (A). A two-layer skin lotion is prepared in the same manner as above.
これらいづれのスキンローションも使用時には内容物を
均一に振盪分散して使用する。When using any of these skin lotions, the contents should be uniformly dispersed by shaking.
（３）特性
各二層型スキンローションの諸試験を実施した結果を第
−表に記載した。(3) Characteristics The results of various tests conducted on each two-layer skin lotion are listed in Table 1.
比較例１〜１４のヒアルロン酸等の酸性ムコ多糖類及び
その塩の一種と、ＧＡＢＡ及びその誘導−１６一
体の一種とを併用配合していないスキンローションに比
較して本発明の実施例１〜１０の皮膚化粧料は諸試験に
おいて明らかに良好なる効果が認められた。Examples 1 to 14 of the present invention compared to skin lotions in which an acidic mucopolysaccharide such as hyaluronic acid and one kind of its salt, and one kind of GABA and its derivative-16 are not combined in Comparative Examples 1 to 14. Skin cosmetics No. 10 were found to have clearly good effects in various tests.
酸性ムコ多糖類及びその塩とγ−アミノ酪酸及びその誘
導体とを併用配合した皮膚化粧料は、優れた皮膚機能亢
進作用を有することは明らかである。It is clear that a skin cosmetic containing a combination of acidic mucopolysaccharides and their salts and γ-aminobutyric acid and its derivatives has an excellent skin function-enhancing effect.
比較例１５〜２１、実施例１１〜１５
〔スキンクリーム〕
実施例１と同様に、下記の組成にて各々のスキンクリー
ムを調製し、諸試験を実施して結果を第２表右欄に示し
た。Comparative Examples 15 to 21, Examples 11 to 15 [Skin cream] In the same manner as in Example 1, each skin cream was prepared with the following composition and various tests were conducted, and the results are shown in the right column of Table 2. Ta.
（２）調製法
前記実施例の二層型スキンローションど同様に、（Ｂ）
成分の内、水溶性の物質は予め（Ｃ）成分中に混合溶解
せしめ、また、油溶性物質は（Ａ）成分中に混合せしめ
、更に、（Ｄ）成分を（Ｃ）成分に混合溶解した水相成
分と、（＾）成分の油相成分をそれぞれ８０°Ｃに加熱
溶融し、撹拌しながら水相成分を油相成分中に加え、乳
化混合した後、更に撹拌しなから３０°Ｃまで冷却して
各々スキンクリ−を調製した。(2) Preparation method As with the two-layer skin lotion in the previous example, (B)
Among the components, water-soluble substances were mixed and dissolved in component (C) in advance, oil-soluble substances were mixed in component (A), and further, component (D) was mixed and dissolved in component (C). Heat and melt the aqueous phase component and the oil phase component of component (^) at 80°C, add the aqueous phase component into the oil phase component while stirring, emulsify and mix, and then heat to 30°C without stirring. Each skin cream was prepared by cooling to
（３）特性
第２表に示す如く、本発明の皮膚化粧料である施例ＩＩ
〜１５のスキンクリームは、比較例１５゜〜２１と比較
して緒特性の全てに亘って優れていることは明らかであ
り、配合特性に於いても異常は認められなかった。(3) Characteristics As shown in Table 2, Example II is a skin cosmetic of the present invention.
It is clear that the skin creams No. 15 to 15 are superior in all physical properties compared to Comparative Examples 15 to 21, and no abnormality was observed in the blending properties.
（発明の効果）
以上記載の如く、本発明の皮膚化粧料は、皮膚機能を充
進し、皮膚の老化防止に顕著な効果を発現する優れた皮
膚化粧料を提供することは明らかである。(Effects of the Invention) As described above, it is clear that the skin cosmetic of the present invention provides an excellent skin cosmetic that improves skin functions and exhibits a remarkable effect on preventing skin aging.
Claims (2)
一種と、γ−アミノ酪酸及びその誘導体より選ばれた少
なくとも一種とを配合したことを特徴とした皮膚化粧料
。(1) A skin cosmetic comprising at least one type of low molecular weight acidic mucopolysaccharide and its salt, and at least one selected from γ-aminobutyric acid and its derivatives.
〜１０００００のヒアルロン酸、平均分子量２００〜２
００００のコンドロイチン硫酸、デルマタン硫酸及びヘ
パラン硫酸である特許請求の範囲第１項に記載の皮膚化
粧料。(2) The low molecular weight acidic mucopolysaccharide has an average molecular weight of 1000
~100,000 hyaluronic acid, average molecular weight 200-2
0000 chondroitin sulfate, dermatan sulfate, and heparan sulfate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29816086A JPS63150209A (en) | 1986-12-15 | 1986-12-15 | Skin cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29816086A JPS63150209A (en) | 1986-12-15 | 1986-12-15 | Skin cosmetic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63150209A true JPS63150209A (en) | 1988-06-22 |
| JPH0465047B2 JPH0465047B2 (en) | 1992-10-16 |
Family
ID=17855973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP29816086A Granted JPS63150209A (en) | 1986-12-15 | 1986-12-15 | Skin cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63150209A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733635A (en) * | 1993-07-21 | 1995-02-03 | Kao Corp | Skin external preparation |
| JPH07242530A (en) * | 1994-03-03 | 1995-09-19 | Kanebo Ltd | Skin cosmetic |
| WO1998019663A1 (en) * | 1996-11-04 | 1998-05-14 | Apr Applied Pharma Research S.A. | Compositions for topical use containing polysaccharide sulphates |
| FR2767692A1 (en) * | 1997-09-01 | 1999-03-05 | Oreal | USE OF A AGONIST SUBSTANCE OF A RECEPTOR ASSOCIATED WITH A CHLORINE OR POTASSIAL CHANNEL IN THE TREATMENT OF SENSITIVE SKIN |
| WO2006101030A1 (en) * | 2005-03-22 | 2006-09-28 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, method for producing same, and cosmetic preparation and food composition containing same |
| WO2007099830A1 (en) * | 2006-02-24 | 2007-09-07 | Q.P. Corporation | Novel low molecular weight hyaluronic acid and/or salt thereof, and cosmetic preparation, pharmaceutical composition and food composition each using same |
| JP2010511021A (en) * | 2006-11-30 | 2010-04-08 | コーエン，マルセル | Use of gamma aminobutyric acid as a depigmenting agent. |
| US20110288047A1 (en) * | 2008-11-20 | 2011-11-24 | Laboratori Derivati Organici Spa | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
| KR20180113935A (en) * | 2017-04-07 | 2018-10-17 | (주)유레 | Method for preparing low molecular weight hyaluronic acid |
| IT202000008299A1 (en) * | 2020-04-17 | 2021-10-17 | Glycores 2000 Srl | Liquid ophthalmic composition comprising linear low molecular weight hyaluronic acid |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008047779A1 (en) * | 2006-10-17 | 2008-04-24 | Glycoscience Laboratories, Inc. | Therapeutic or prophylactic agent for atopic dermatitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5452733A (en) * | 1977-10-04 | 1979-04-25 | Pola Kasei Kogyo Kk | Skin cosmetics |
| JPS5826726A (en) * | 1981-08-05 | 1983-02-17 | Hitachi Plant Eng & Constr Co Ltd | Apparatus for feeding powder |
| JPS60184005A (en) * | 1984-03-02 | 1985-09-19 | Kanebo Ltd | Cosmetic for preventing aging of skin |
-
1986
- 1986-12-15 JP JP29816086A patent/JPS63150209A/en active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5452733A (en) * | 1977-10-04 | 1979-04-25 | Pola Kasei Kogyo Kk | Skin cosmetics |
| JPS5826726A (en) * | 1981-08-05 | 1983-02-17 | Hitachi Plant Eng & Constr Co Ltd | Apparatus for feeding powder |
| JPS60184005A (en) * | 1984-03-02 | 1985-09-19 | Kanebo Ltd | Cosmetic for preventing aging of skin |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733635A (en) * | 1993-07-21 | 1995-02-03 | Kao Corp | Skin external preparation |
| JPH07242530A (en) * | 1994-03-03 | 1995-09-19 | Kanebo Ltd | Skin cosmetic |
| WO1998019663A1 (en) * | 1996-11-04 | 1998-05-14 | Apr Applied Pharma Research S.A. | Compositions for topical use containing polysaccharide sulphates |
| FR2767692A1 (en) * | 1997-09-01 | 1999-03-05 | Oreal | USE OF A AGONIST SUBSTANCE OF A RECEPTOR ASSOCIATED WITH A CHLORINE OR POTASSIAL CHANNEL IN THE TREATMENT OF SENSITIVE SKIN |
| WO1999011238A1 (en) * | 1997-09-01 | 1999-03-11 | L'oreal | Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins |
| US6572848B1 (en) | 1997-09-01 | 2003-06-03 | Societe L'oreal S.A. | Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins |
| JP4576583B2 (en) * | 2005-03-22 | 2010-11-10 | キユーピー株式会社 | Hyaluronic acid or a salt thereof, method for producing the same, and cosmetics and food compositions containing the same |
| WO2006101030A1 (en) * | 2005-03-22 | 2006-09-28 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, method for producing same, and cosmetic preparation and food composition containing same |
| JP2006265287A (en) * | 2005-03-22 | 2006-10-05 | Q P Corp | Low molecular weight hyaluronic acid and/or its salt, its manufacturing process and cosmetic and food composition containing it |
| US8933054B2 (en) | 2005-03-22 | 2015-01-13 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, method for producing same, and cosmetic preparation and food composition containing same |
| JP5289936B2 (en) * | 2006-02-24 | 2013-09-11 | キユーピー株式会社 | Novel low molecular weight hyaluronic acid and / or salt thereof, and cosmetics, pharmaceutical compositions and food compositions using the same |
| WO2007099830A1 (en) * | 2006-02-24 | 2007-09-07 | Q.P. Corporation | Novel low molecular weight hyaluronic acid and/or salt thereof, and cosmetic preparation, pharmaceutical composition and food composition each using same |
| US8367818B2 (en) | 2006-02-24 | 2013-02-05 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, and cosmetic preparation, pharmaceutical composition, and food composition each using same |
| JP2010511021A (en) * | 2006-11-30 | 2010-04-08 | コーエン，マルセル | Use of gamma aminobutyric acid as a depigmenting agent. |
| US20110288047A1 (en) * | 2008-11-20 | 2011-11-24 | Laboratori Derivati Organici Spa | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
| JP2012509289A (en) * | 2008-11-20 | 2012-04-19 | ラボラトリ・デリバティ・オルガニシ・エス・ピー・エイ | Process for the purification of heparan sulfate and its use in cosmetic and dermatological preparations |
| US9440099B2 (en) * | 2008-11-20 | 2016-09-13 | Laboratori Derivati Organici Spa | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
| JP2017043638A (en) * | 2008-11-20 | 2017-03-02 | ラボラトリ・デリバティ・オルガニシ・エス・ピー・エイ | Process for purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
| KR20180113935A (en) * | 2017-04-07 | 2018-10-17 | (주)유레 | Method for preparing low molecular weight hyaluronic acid |
| CN110431155A (en) * | 2017-04-07 | 2019-11-08 | 优瑞有限公司 | The preparation method of low-molecular-weight hyaluronic acid |
| EP3608343A4 (en) * | 2017-04-07 | 2020-11-04 | Youreh Co., Ltd. | Method for preparing low molecular weight hyaluronic acid |
| IT202000008299A1 (en) * | 2020-04-17 | 2021-10-17 | Glycores 2000 Srl | Liquid ophthalmic composition comprising linear low molecular weight hyaluronic acid |
| WO2021209974A1 (en) * | 2020-04-17 | 2021-10-21 | Glycores 2000 S.R.L. | Process for the preparation of low molecular weight linear hyaluronic acid and hyaluronic acid so obtained |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0465047B2 (en) | 1992-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110664644B (en) | Skin care composition containing folic acid, essence and preparation method thereof | |
| JPH10182412A (en) | External-use medical preparation | |
| KR20190010795A (en) | Moisturizing, anti-wrinkling, and whitening cosmetic composition comprising novel Hyalpol Matrix Mixture and preparation method of the same | |
| JPS63150209A (en) | Skin cosmetic | |
| JP3922311B2 (en) | Skin aging prevention cosmetics | |
| KR20050103903A (en) | Topical composition and methods for treatment of aged or environmentally damaged skin | |
| JPH06104620B2 (en) | Skin cosmetics | |
| CN111012699A (en) | Antioxidant oil-controlling emulsion containing fucoidan-kelp extract | |
| JP2511820B2 (en) | Skin cosmetics | |
| JP3507635B2 (en) | Composition suitable for external use | |
| JPH0146483B2 (en) | ||
| JPS60116618A (en) | Cosmetic | |
| JPS63150210A (en) | Hair-tonic cosmetic | |
| JP2553474B2 (en) | Skin cosmetics | |
| JPS6281307A (en) | Skin cosmetic | |
| JP2511817B2 (en) | Skin cosmetics | |
| JP2004075635A (en) | Moisturizing agent and external preparation for skin | |
| JPS62138411A (en) | Cosmetic for preventing skin from ageing | |
| JPS62148414A (en) | Skin cosmetic | |
| JPS63139104A (en) | Skin cosmetic | |
| JPS62153206A (en) | Skin cosmetic | |
| JPS62249912A (en) | Skin cosmetic | |
| JPS6368512A (en) | Skin drug for external use | |
| RU2007163C1 (en) | Agent for washing head and body | |
| JPH03200707A (en) | Dermal external agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |